ArticleFrontiers in pharmacology2022

Immunotherapeutic Value of MAP1LC3C and Its Candidate FDA-Approved Drugs Identified by Pan-Cancer Analysis, Virtual Screening and Sensitivity Analysis.

Xudong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.